ANI Pharma Inc (ANIP)

$84.83 -0.46 (-0.54%)
Market Cap 1.91B
Revenue (ttm) 614.38M
Net Income (ttm) -18.52M
EPS (ttm) N/A
PE Ratio 14.33
Forward PE 12.28
Profit Margin -3.01%
Debt to Equity Ratio 0.62
Volume 517,800
Avg Vol 472,554
Day's Range N/A - N/A
Shares Out 22.47M
Stochastic %K 86%
Beta 0.51
Analysts Strong Sell
Price Target $109.25

Company Profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chain...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 218 634 3500
Fax: 218 634 3540
Address:
210 Main Street West, Baudette, United States
ZacksResearch
ZacksResearch Jan. 16 at 1:53 PM
$ANIP vs. $TEVA — Which pharma stock should you buy? 💊 ANI Pharmaceuticals is riding high on Cortrophin Gel’s progress, projecting a 55-65% sales increase in 2026, paired with a Zacks Rank #2 (Buy). In contrast, TEVA maintains its biosimilars strategy, with a Zacks Rank #3 (Hold). See what makes ANIP stand out as an investment pick 👉 https://www.zacks.com/stock/news/2818642/anip-vs-teva-which-drug-stock-is-the-better-buy-right-now?cid=sm-stocktwits-2-2818642-body-29206&ADID=SYND_STOCKTWITS_TWEET_2_2818642_BODY_29206
0 · Reply
ZacksResearch
ZacksResearch Jan. 16 at 12:53 PM
$ANIP vs. $TEVA — which drug stock actually deserves your capital right now? 💊⚖️ This head-to-head breaks down the investment case between ANI Pharmaceuticals and Teva, framing which name stands out as the better buy in the current setup. See how the comparison stacks up and which stock comes out ahead 👉 https://www.zacks.com/stock/news/2818642/anip-vs-teva-which-drug-stock-is-the-better-buy-right-now?cid=sm-stocktwits-2-2818642-teaser-29205&ADID=SYND_STOCKTWITS_TWEET_2_2818642_TEASER_29205
0 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 1:33 PM
ANIP ripping higher — 7% in a week and investors aren’t guessing 🚀 $ANIP is moving after 2026 guidance topped expectations, supported by strong sales and EPS growth fueled by continued momentum in its rare disease franchise. Dig into what’s driving the upside and what it means from here 👉 https://www.zacks.com/stock/news/2817833/anip-stock-rises-7-in-a-week-heres-what-you-should-know?cid=sm-stocktwits-2-2817833-teaser-28974&ADID=SYND_STOCKTWITS_TWEET_2_2817833_TEASER_28974
0 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 12:33 PM
$ANIP up 7% on killer 2026 guidance! 🚀 👀 2026 EPS forecasted at $8.83-$9.34, aiming for 20-22% growth over 2025. 💊 Rare disease portfolio expected to drive 60% of 2026 sales. 📈 Cortrophin Gel sales set to jump 55-65% with expanded demand. Discover more about ANIP's position in the market 👉 https://www.zacks.com/stock/news/2817833/anip-stock-rises-7-in-a-week-heres-what-you-should-know?cid=sm-stocktwits-2-2817833-body-28972&ADID=SYND_STOCKTWITS_TWEET_2_2817833_BODY_28972
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 13 at 10:03 PM
$ANIP RSI: 53.05, MACD: -0.7021 Vol: 2.05, MA20: 80.72, MA50: 83.13 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ortega1963
ortega1963 Jan. 13 at 12:38 PM
$ANIP back to 100
0 · Reply
CunningStunt69
CunningStunt69 Jan. 12 at 4:40 PM
$ANIP no idea what the market has been thinking here since last earnings, but back over $100 I think
0 · Reply
Oratory
Oratory Jan. 12 at 4:24 PM
$ANIP No position here, but... nice move!
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 12 at 4:15 PM
$AMC $PCRX $ANIP $DX
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 12 at 4:08 PM
$ANIP Cycle Trading Signal 🔥 app 🔥
0 · Reply
Latest News on ANIP
ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 8:35 PM EST - 2 days ago

ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance

Jan 13, 2026, 11:53 AM EST - 3 days ago

ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities

Jan 12, 2026, 6:50 AM EST - 4 days ago

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 4:15 PM EST - 10 days ago

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise

Dec 2, 2025, 6:50 AM EST - 6 weeks ago

ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise

ANI Pharmaceuticals Announces Board Transition

Dec 1, 2025, 6:50 AM EST - 6 weeks ago

ANI Pharmaceuticals Announces Board Transition

ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 6:50 AM EST - 7 weeks ago

ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference

ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London

Nov 11, 2025, 4:05 PM EST - 2 months ago

ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London

ANI Pharmaceuticals, Inc. (ANIP) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 2:16 PM EST - 2 months ago

ANI Pharmaceuticals, Inc. (ANIP) Q3 2025 Earnings Call Transcript

ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance

Nov 7, 2025, 6:50 AM EST - 2 months ago

ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates

Oct 28, 2025, 5:54 PM EDT - 2 months ago

ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates

ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET

Oct 24, 2025, 6:50 AM EDT - 3 months ago

ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting

Oct 16, 2025, 6:50 AM EDT - 3 months ago

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting

ANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 4:41 PM EDT - 4 months ago

ANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

Aug 25, 2025, 4:30 PM EDT - 5 months ago

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:56 PM EDT - 5 months ago

ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

Aug 8, 2025, 6:50 AM EDT - 5 months ago

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET

Aug 1, 2025, 6:50 AM EDT - 6 months ago

ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

Jul 23, 2025, 6:50 AM EDT - 6 months ago

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

Jul 2, 2025, 6:50 AM EDT - 7 months ago

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

Jun 12, 2025, 7:00 AM EDT - 7 months ago

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 27, 2025, 4:30 PM EDT - 8 months ago

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

May 27, 2025, 7:20 AM EDT - 8 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

AGL OMER

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

May 22, 2025, 6:50 AM EDT - 8 months ago

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

May 12, 2025, 6:30 PM EDT - 8 months ago

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript

May 9, 2025, 11:44 AM EDT - 9 months ago

ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

May 9, 2025, 6:50 AM EDT - 9 months ago

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals: A Short-Term Buying Opportunity

May 6, 2025, 5:43 AM EDT - 9 months ago

ANI Pharmaceuticals: A Short-Term Buying Opportunity

ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model

May 5, 2025, 7:00 AM EDT - 9 months ago

ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

Apr 9, 2025, 6:50 AM EDT - 10 months ago

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 31, 2025, 4:30 PM EDT - 10 months ago

ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

Mar 19, 2025, 6:50 AM EDT - 10 months ago

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®

Mar 18, 2025, 6:50 AM EDT - 10 months ago

ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

Mar 14, 2025, 6:50 AM EDT - 11 months ago

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe

Mar 3, 2025, 4:30 PM EST - 11 months ago

ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe

ANI Pharmaceuticals, Inc. (ANIP) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 5:45 PM EST - 11 months ago

ANI Pharmaceuticals, Inc. (ANIP) Q4 2024 Earnings Call Transcript

ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast

Feb 28, 2025, 10:37 AM EST - 11 months ago

ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast

ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

Feb 28, 2025, 6:50 AM EST - 11 months ago

ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March

Feb 19, 2025, 4:30 PM EST - 11 months ago

ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

Feb 18, 2025, 4:05 PM EST - 11 months ago

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

ANI Pharmaceuticals: More Than Just A Generics Company

Feb 11, 2025, 9:08 AM EST - 1 year ago

ANI Pharmaceuticals: More Than Just A Generics Company

ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

Jan 28, 2025, 4:30 PM EST - 1 year ago

ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

Alcami Announces CEO Transition

Jan 13, 2025, 11:12 AM EST - 1 year ago

Alcami Announces CEO Transition

ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

Jan 13, 2025, 6:50 AM EST - 1 year ago

ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity

Jan 2, 2025, 6:50 AM EST - 1 year ago

ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity

ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 30, 2024, 4:05 PM EST - 1 year ago

ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference

Nov 26, 2024, 4:30 PM EST - 1 year ago

ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference

ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 11:05 PM EST - 1 year ago

ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

Nov 8, 2024, 6:50 AM EST - 1 year ago

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November

Nov 4, 2024, 4:30 PM EST - 1 year ago

ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November

ZacksResearch
ZacksResearch Jan. 16 at 1:53 PM
$ANIP vs. $TEVA — Which pharma stock should you buy? 💊 ANI Pharmaceuticals is riding high on Cortrophin Gel’s progress, projecting a 55-65% sales increase in 2026, paired with a Zacks Rank #2 (Buy). In contrast, TEVA maintains its biosimilars strategy, with a Zacks Rank #3 (Hold). See what makes ANIP stand out as an investment pick 👉 https://www.zacks.com/stock/news/2818642/anip-vs-teva-which-drug-stock-is-the-better-buy-right-now?cid=sm-stocktwits-2-2818642-body-29206&ADID=SYND_STOCKTWITS_TWEET_2_2818642_BODY_29206
0 · Reply
ZacksResearch
ZacksResearch Jan. 16 at 12:53 PM
$ANIP vs. $TEVA — which drug stock actually deserves your capital right now? 💊⚖️ This head-to-head breaks down the investment case between ANI Pharmaceuticals and Teva, framing which name stands out as the better buy in the current setup. See how the comparison stacks up and which stock comes out ahead 👉 https://www.zacks.com/stock/news/2818642/anip-vs-teva-which-drug-stock-is-the-better-buy-right-now?cid=sm-stocktwits-2-2818642-teaser-29205&ADID=SYND_STOCKTWITS_TWEET_2_2818642_TEASER_29205
0 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 1:33 PM
ANIP ripping higher — 7% in a week and investors aren’t guessing 🚀 $ANIP is moving after 2026 guidance topped expectations, supported by strong sales and EPS growth fueled by continued momentum in its rare disease franchise. Dig into what’s driving the upside and what it means from here 👉 https://www.zacks.com/stock/news/2817833/anip-stock-rises-7-in-a-week-heres-what-you-should-know?cid=sm-stocktwits-2-2817833-teaser-28974&ADID=SYND_STOCKTWITS_TWEET_2_2817833_TEASER_28974
0 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 12:33 PM
$ANIP up 7% on killer 2026 guidance! 🚀 👀 2026 EPS forecasted at $8.83-$9.34, aiming for 20-22% growth over 2025. 💊 Rare disease portfolio expected to drive 60% of 2026 sales. 📈 Cortrophin Gel sales set to jump 55-65% with expanded demand. Discover more about ANIP's position in the market 👉 https://www.zacks.com/stock/news/2817833/anip-stock-rises-7-in-a-week-heres-what-you-should-know?cid=sm-stocktwits-2-2817833-body-28972&ADID=SYND_STOCKTWITS_TWEET_2_2817833_BODY_28972
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 13 at 10:03 PM
$ANIP RSI: 53.05, MACD: -0.7021 Vol: 2.05, MA20: 80.72, MA50: 83.13 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ortega1963
ortega1963 Jan. 13 at 12:38 PM
$ANIP back to 100
0 · Reply
CunningStunt69
CunningStunt69 Jan. 12 at 4:40 PM
$ANIP no idea what the market has been thinking here since last earnings, but back over $100 I think
0 · Reply
Oratory
Oratory Jan. 12 at 4:24 PM
$ANIP No position here, but... nice move!
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 12 at 4:15 PM
$AMC $PCRX $ANIP $DX
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 12 at 4:08 PM
$ANIP Cycle Trading Signal 🔥 app 🔥
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 12 at 1:51 PM
$ANIP (+10.2% pre) ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities https://ooc.bz/l/89367
0 · Reply
cynicaloptimist
cynicaloptimist Jan. 12 at 12:52 PM
@Jblack500 @MaverikIT @WAJeff $ANIP making pre market move
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 11 at 10:58 PM
$AMC $PCRX $ANIP $DX 🔥 Cycle Trading Signal 🔥 app 🔥 with momentum trigger buy and pullback signal 🔥
0 · Reply
roddy5
roddy5 Jan. 11 at 1:15 PM
$ANIP it remains a mistery why the stock declined so much after outstanding q3 results . Really weird!!
1 · Reply
Victor224
Victor224 Jan. 11 at 12:23 PM
$ANIP Has much news they could release this week at the JPM Healthcare Conference. In addition to new regarding Inzirqo, Tezrully and possibly Libigel, they could give a top line readout for the Synchronicity study. Good results could be the reason ANIP established the FutureVision Advisory Council to help guide their strategic advancement of its ophthalmology and retina franchise within their Rare Disease business. This steering committee includes seven retina specialists and three uveitis globally recognized leaders in their respective fields.
0 · Reply
WestEgg
WestEgg Jan. 9 at 7:13 PM
$ANIP Timmmmmberrrrr!
0 · Reply
WestEgg
WestEgg Jan. 9 at 4:18 PM
$ANIP Timmmberrrrr!
0 · Reply
Dy2ski
Dy2ski Jan. 6 at 9:19 PM
$ANIP https://investor.anipharmaceuticals.com/news-releases/news-release-details/ani-pharmaceuticals-present-44th-annual-jp-morgan-healthcare Tuesday...decent slot time. Let's hope they have some great news to share and give the market a very bullish outlook for 2026!
0 · Reply
ZacksResearch
ZacksResearch Jan. 6 at 6:29 PM
$ANIP up 21% in just six months — is this rare-disease momentum still investable? 🔥 Strong 2025 results, repeated earnings beats, and higher guidance are driving confidence as ANI Pharmaceuticals builds momentum in its rare diseases portfolio. Is this rally just getting started — or already priced in? Full breakdown here 👉 https://www.zacks.com/stock/news/2812753/anip-up-21-in-6-months-is-it-worth-investing-in-the-stock-now?cid=sm-stocktwits-2-2812753-teaser-27634&ADID=SYND_STOCKTWITS_TWEET_2_2812753_TEASER_27634
0 · Reply
ZacksResearch
ZacksResearch Jan. 6 at 5:29 PM
$ANIP: Riding the Rare Disease Wave for Big Gains! 🚀 Q3 saw ANIP beat sales and earnings, raising their FY2025 guidance, with expected EPS growth of 42-47% and sales up 39-42%. The rare disease franchise more than doubled its year-over-year revenue 📈. Discover the full potential here 👉 https://www.zacks.com/stock/news/2812753/anip-up-21-in-6-months-is-it-worth-investing-in-the-stock-now?cid=sm-stocktwits-2-2812753-body-27633&ADID=SYND_STOCKTWITS_TWEET_2_2812753_BODY_27633
0 · Reply
WestEgg
WestEgg Jan. 3 at 3:31 PM
$ANIP Timberrrrr!
0 · Reply
Victor224
Victor224 Jan. 2 at 11:58 AM
$ANIP In addition to increasing rare disease sales growth the following 2026 catalyst should drive ANIP growth: - Announcing sales from Inzirqo and Tezruly both NDAs approved in 2025, but not announced. Insurance coverage for the drugs is growing and both have patent coverage until early 2040s. - Libigel trademark which had been abandoned was issued to ANIP in December. Libigel could become the first FDA approved female testosterone in 2026. FDA is facing mounting pressure to approve a testosterone option designed for women. If not already submitted (ANIP has one outstanding NDA submission from Q3 2023, which appears to have been financed by a third party) It could qualify for the FDA Commissioner's National Priority Voucher (CNPV) Pilot Program, with review completed within 2 months. - Announcing large pharma partner (possibly Merck) . ANIP has maintained a vacant BOD seat over the last two annual meetings. Likely for the partner who funded the NDA submission in 2023.
1 · Reply